Venture Capital

Three industry titans launch AlphaDrive, a $100M fund blending VC and private equity to back the next generation of Israeli Cyber-AI startups.

CoTec Holdings Corp. joins the OTCQX market, a key step in attracting U.S. investment for its disruptive tech aimed at recycling rare earth magnets.

With its 100th study launch and a perfect client retention rate, Atreo's agile RTSM platform is challenging the rigid, slow pace of traditional trial tech.

A new $50M fund unites venture capital with Canada's top cancer charities, aiming to fast-track lab discoveries into life-saving patient treatments.

As AI fakes threaten truth, Reality Defender recruits pioneers from Google, Twitter, and academia to build an ethical framework for detection technology.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

Giyani Metals' high-purity manganese meets quality standards from US tech leader C4V, a crucial step in building a non-Chinese battery supply chain.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

UK biotech Cytospire secures a major Series A to bring its novel pan-gamma delta T cell engagers, targeting tough solid tumors, into clinical trials.

The clean energy vehicle company is assembling a top-tier team to develop hydrogen-powered drones, aiming for a slice of the $182 billion UGV market.

Finnish tech firm Eficode secures Atlassian's top partner award, highlighting its leadership in AI-driven software development and global market expansion.

Marking its 10th anniversary, The War Zone rebrands to TWZ, expanding its digital footprint to meet growing demand for in-depth defense journalism.

The FPGA maker is acquiring firmware leader AMI, aiming to create a complete security and control platform for the booming AI and cloud infrastructure market.

As Spruce Power preps its Q1 results, investors watch to see how the firm is navigating the end of key tax credits and rising competition.

Valion Bio's new General Counsel, a rare blend of scientist and lawyer, is poised to navigate its radiation drug through the FDA's complex Animal Rule.

Bill Ackman's ambitious Pershing Square USA fund saw a rocky NYSE launch, even as it drew high-profile global investors like Mexico's Jack Landsmanas.

Zyphra, AMD, and TensorWave partner to launch a new AI platform, targeting complex, long-horizon agentic workloads and challenging the AI infrastructure market.

CTIBIOTECH brings revolutionary 3D human tissue printing to 'Cellicon Valley,' aiming to slash drug failures and accelerate personalized medicine.

The investment firm navigated global volatility to post a €1.3M profit, while its hydro plant reveals the paradox of climate risk and market gains.